Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Published Online: 2020-11-?
Journal: The Lancet Respiratory Medicine•Publisher: Elsevier BV
Authors: Amelia Insa Molla•Andreas Johne•Anne-Marie Dingemans•Antonio Calles Blanco•Azura Rozila Ahmad•Byoung Chul Cho•Cheng-Ta Yang•Chih-Feng Chian•Chih-Feng Chian•Chih-Hsin Yang•Chin-Chou Wang•Chong Kin Liam•Daniel Shao Weng Tan•Dong-Wan Kim•Dong-Wan Kim•Enriqueta Felip Font•Filippo de Marinis•Gee-Chen Chang•Helong Zhang•Ho Jung An•Hongming Pan•Hongming Pan•In Sook Woo•Jae Yong Cho•James Chih-Hsin Yang•Jian Fang•Jianying Zhou•Jianying Zhou•Jong-Seok Lee•Joo-Hang Kim•Josef Straub•Jun Zhao•Jun Zhao•Jürgen Scheele•Kananathan Ratnavelu•Keunchil Park•Keunchil Park•Ki Hyeong Lee•Lynette Si-Mien Ngo•Lynne Bui•Martin Emilio Lazaro Quintela•Mengzhao Wang•Naofumi Shinagawa•Pierfrancesco Tassone•Rolf Bruns•Ross Andrew Soo•Ross Andrew Soo•Sang Won Shin•Sang-We Kim•Sang-We Kim•Seung Soo Yoo•Shao Weng Daniel Tan•Shiying Yu•Shun Lu•Shun Lu•Te-Chun Hsia•Terufumi Kato•Wei Li•Xi Chen•Xiaoqing Liu•Xiaoqing Liu•Yi-Long Wu•Yi-Long Wu•Ying Cheng•Ying Cheng•Yiping Zhang•Yiping Zhang•Young-Chul Kim•Yuh-Min Chen•Yuh-Min Chen•Zhe Liu
